The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance

With sunitinib treatment of metastatic renal cell carcinoma, most patients end up developing resistance over time. Recent clinical trials have shown that individualizing treatment protocols could delay resistance and result in better outcomes. We developed an in vivo xenograft tumor model and compar...

Full description

Bibliographic Details
Main Authors:	Harrison Sicheng Lin, Qiang Ding, Zsuzsanna Lichner, Sung Sun Kim, Rola Saleeb, Mina Farag, Ashley Di Meo, Pamela Plant, Mirit Kaldas, Georg Arnold Bjarnason, George Makram Yousef
Format:	Article
Language:	English
Published:	MDPI AG 2022-01-01
Series:	Journal of Clinical Medicine
Subjects:	renal cell carcinoma sunitinib resistance treatment scheduling
Online Access:	https://www.mdpi.com/2077-0383/11/2/369

Similar Items

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
by: Zhu X, et al.
Published: (2021-08-01)

Potential for use sunitinib in pancreatic neuroendocrine tumors
by: A. A. Markovich, et al.
Published: (2019-06-01)

Metastatic collecting duct carcinoma of the kidney treated with sunitinib
by: M'rabti Hind, et al.
Published: (2011-07-01)

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial
by: Guillaume Mouillet, et al.
Published: (2018-04-01)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
by: Antonello Di Paolo, et al.
Published: (2017-08-01)

Pneumatosis cystoides intestinalis linked to sunitinib treatment for renal cell carcinoma
by: Hiroyuki Shikuma, et al.
Published: (2019-11-01)

A significant response to sunitinib in a patient with anaplastic thyroid carcinoma
by: Enrique Grande, et al.
Published: (2013-01-01)

Photochemically-Induced Release of Lysosomal Sequestered Sunitinib: Obstacles for Therapeutic Efficacy
by: Judith Jing Wen Wong, et al.
Published: (2020-02-01)

Sunitinib resistance in renal cell carcinoma
by: Christudas Morais
Published: (2014-04-01)

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
by: Keyvanjah Kiana, et al.
Published: (2012-08-01)

Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma
by: Se Woong Choi, et al.
Published: (2020-02-01)

Sunitinib for adenocarcinoma of the rete testis: a case report
by: Kezhen Li, et al.
Published: (2024-04-01)

Development and validation of a HPTLC method for analysis of Sunitinib malate
by: Monireh Hajmalek, et al.

Sunitinib in pancreatic neuroendocrine tumors. Clinical case
by: A. A. Markovich, et al.
Published: (2019-12-01)

Impact of Sunitinib on Human Thyroid Cancer Cells
by: Jirka Grosse, et al.
Published: (2013-07-01)

SIDE EFFECTS OF SUNITINIB MANIFESTED ON SKIN OF PATIENTS DIAGNOSED WITH RENAL CELL CARCINOMA: CASE-CONTROL STUDY
by: Bojana Petrović, et al.
Published: (2009-10-01)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
by: Maud Maillard, et al.
Published: (2022-09-01)

Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report
by: Alexandra Karadimou, et al.
Published: (2011-08-01)

Effect of enhanced expression of connexin 43 on sunitinib-induced cytotoxicity in mesothelioma cells
by: Miaki Uzu, et al.
Published: (2015-05-01)

Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate
by: Joan Manel Gasent Blesa, et al.
Published: (2009-12-01)

Sunitinib efficacy with minimal toxicity in patient-derived retinoblastoma organoids
by: Atthapol Srimongkol, et al.
Published: (2023-02-01)

Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib
by: Ying-Shou Chen, et al.
Published: (2009-10-01)

Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats
by: Mohammad Nasser Hashemian, et al.
Published: (2017-01-01)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
by: Tomonori Sato, et al.
Published: (2020-12-01)

The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
by: Rafia S. Al-Lamki, et al.
Published: (2020-04-01)

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
by: Giovanni Luca Gravina, et al.
Published: (2017-01-01)

Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients
by: Romualdo Barroso-Sousa, et al.
Published: (2014-12-01)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
by: Akihiro Yoshimura, et al.
Published: (2020-09-01)

Preclinical evaluation of Sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases
by: Schem Christian, et al.
Published: (2013-01-01)

Concurrent hand-foot skin reaction and hair depigmentation with sunitinib: Report of a case and literature review of kinase inhibitors and blocking antibodies
by: Shuchi Bansal, et al.
Published: (2014-01-01)

Key sunitinib‐related biomarkers for renal cell carcinoma
by: Yun Peng, et al.
Published: (2021-10-01)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
by: Jun Guo, et al.
Published: (2018-05-01)

Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment
by: Pavla Bouchalova, et al.
Published: (2021-09-01)

Sunitinib induced hepatotoxicity in L02 cells via ROS-MAPKs signaling pathway
by: Ting-Li Tang, et al.
Published: (2022-10-01)

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients
by: Michal Rihacek, et al.
Published: (2022-06-01)

Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models
by: Devalingam Mahalingam, et al.
Published: (2019-06-01)

An Interesting Case: Sunitinib-Induced Microangiopathic Hemolytic Anemia and Nephrotic Syndrome
by: Veysel Haksöyler, et al.
Published: (2021-06-01)

From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib
by: Amal Kamal Abdel-Aziz, et al.
Published: (2017-10-01)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
by: Que Y, et al.
Published: (2018-07-01)

Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study
by: Yanli Wang, et al.
Published: (2023-11-01)